Headlines & Global News
FDA Reviewers Recommend Against Approval For Novartis Heart Failure Drug
On Thursday the FDA's Cardiovascular and Renal Drugs Advisory Committee will discuss the biologics license application (BLA) for serelaxin injection (proposed trade name Reasanz) from Novartis. The indication is for the improvement of the symptoms of ...
FDA staff review recommends against Novartis heart failure drug